Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a fireside chat at the BofA Securities Biotech SMID Cap Conference on Thursday, December 8, 2022, from 8:00-8:30am ET.
Related news for (INZY)
- 24/7 Market News Snapshot 16 May, 2025 – Inozyme Pharma, Inc. Common Stock (NASDAQ:INZY)
- Top Breakout Stocks to Trade: Amesite, Siyata Mobile, Quantum Computing, Archer Aviation, Inozyme Pharma, and Applied Digital
- 24/7 Market News Snapshot 16 May, 2025 – Inozyme Pharma, Inc. Common Stock (NASDAQ:INZY)
- Don’t Miss Out: MoBot’s Latest Stock Updates 05/16/25 08:00 AM
- Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights